| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/J.1552-4876.2013.31364.X |
| P698 | PubMed publication ID | 23613428 |
| P50 | author | Charis Eng | Q37385393 |
| P2093 | author name string | Jessica Mester | |
| P2860 | cites work | PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes | Q36008552 |
| Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly | Q36053966 | ||
| Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways | Q36256326 | ||
| The challenges of Proteus syndrome: diagnosis and management | Q36554428 | ||
| Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma | Q36659706 | ||
| Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain | Q36818855 | ||
| Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function. | Q37252731 | ||
| Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. | Q37270416 | ||
| Management of arteriovenous malformations | Q37811535 | ||
| Mechanism of action of the immunosuppressant rapamycin | Q40965429 | ||
| Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes | Q42685048 | ||
| Arteriovenous malformations in Cowden syndrome | Q42999288 | ||
| The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management | Q43232449 | ||
| Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation | Q45345194 | ||
| Germline mutations in PTEN are present in Bannayan-Zonana syndrome | Q48046915 | ||
| Brain magnetic resonance imaging in patients with Cowden syndrome | Q48974595 | ||
| Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly | Q50303516 | ||
| The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly | Q50342128 | ||
| Mutant AKT1 in Proteus syndrome. | Q54546475 | ||
| Monozygotic twins discordant for Proteus syndrome. | Q55050187 | ||
| Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. | Q55463935 | ||
| Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial | Q55981839 | ||
| Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes | Q57591248 | ||
| Localization of the gene for Cowden disease to chromosome 10q22–23 | Q57694734 | ||
| Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model | Q22337253 | ||
| The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate | Q24317714 | ||
| P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 | ||
| Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling | Q24536092 | ||
| A mosaic activating mutation in AKT1 associated with the Proteus syndrome | Q24598593 | ||
| A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands | Q24606333 | ||
| Germline mutation of the tumour suppressor PTEN in Proteus syndrome | Q24672675 | ||
| Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations | Q24673663 | ||
| Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. | Q27824772 | ||
| Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling | Q27851424 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| Cowden's disease. A possible new symptom complex with multiple system involvement | Q28189705 | ||
| Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis | Q28211005 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Pten is essential for embryonic development and tumour suppression | Q28509238 | ||
| Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN | Q28513537 | ||
| LKB1 is the upstream kinase in the AMP-activated protein kinase cascade | Q28610414 | ||
| Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway | Q28646919 | ||
| Cellular survival: a play in three Akts | Q29547806 | ||
| Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome | Q29615538 | ||
| The tuberous sclerosis complex | Q29619128 | ||
| PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model | Q32069431 | ||
| Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy? | Q33674349 | ||
| An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice | Q33943166 | ||
| Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53. | Q34399395 | ||
| Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice | Q34479331 | ||
| PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome | Q34504165 | ||
| Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers | Q34579796 | ||
| Lifetime cancer risks in individuals with germline PTEN mutations. | Q35681689 | ||
| P577 | publication date | 2013-04-09 | |
| P1433 | published in | American Journal of Medical Genetics Part C: Seminars in Medical Genetics | Q15749239 |
| P1476 | title | When Overgrowth Bumps Into Cancer: The PTEN-Opathies |
| Q54977058 | "Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology. |
| Q28546443 | A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity |
| Q41549246 | A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells |
| Q36763145 | A recessive form of extreme macrocephaly and mild intellectual disability complements the spectrum of PTEN hamartoma tumour syndrome |
| Q35201003 | A unified nomenclature and amino acid numbering for human PTEN. |
| Q36512454 | Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells |
| Q37732931 | Alisertib induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt/mTOR- and p38 MAPK-mediated pathways in human glioblastoma cells |
| Q49711107 | Angioarchitecture of Hereditary Arteriovenous Malformations |
| Q35943062 | Autism Linked to Increased Oncogene Mutations but Decreased Cancer Rate. |
| Q35762766 | Autism spectrum disorder and epilepsy: Disorders with a shared biology |
| Q36876219 | Capillary Isoelectric Focusing of Akt Isoforms Identifies Highly Dynamic Phosphorylation in Neuronal Cells and Brain Tissue |
| Q42117867 | Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS |
| Q53829615 | Dynamics and structural stability effects of germline PTEN mutations associated with cancer versus autism phenotypes. |
| Q35885555 | Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications |
| Q35164689 | Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations |
| Q48026123 | Euptox A Induces G1 Arrest and Autophagy via p38 MAPK- and PI3K/Akt/mTOR-Mediated Pathways in Mouse Splenocytes |
| Q36619272 | FGFR and PTEN signaling interact during lens development to regulate cell survival |
| Q57455573 | Gene-specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert Panel |
| Q34008801 | Genetic predisposition to colorectal cancer: where we stand and future perspectives |
| Q90290396 | Genetics of Growth Disorders-Which Patients Require Genetic Testing? |
| Q37626146 | Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells |
| Q27694653 | Impact of NGS in the medical sciences: Genetic syndromes with an increased risk of developing cancer as an example of the use of new technologies |
| Q42317510 | Induction of apoptosis and autophagy via mitochondria- and PI3K/Akt/mTOR-mediated pathways by E. adenophorum in hepatocytes of saanen goat |
| Q42475089 | Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells |
| Q37709054 | Induction of mitochondria-mediated apoptosis and PI3K/Akt/ mTOR-mediated autophagy by aflatoxin B2 in hepatocytes of broilers |
| Q34982418 | Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells |
| Q64075806 | Mechanistic Target of Rapamycin Pathway in Epileptic Disorders |
| Q40740686 | Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy |
| Q39021335 | Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway |
| Q35924047 | Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth. |
| Q41197475 | Oleic acid induces apoptosis and autophagy in the treatment of Tongue Squamous cell carcinomas |
| Q27691998 | Overgrowth Syndromes |
| Q40404987 | PTEN functions by recruitment to cytoplasmic vesicles |
| Q52805958 | PTEN suppresses axon outgrowth by down-regulating the level of detyrosinated microtubules. |
| Q45943092 | Quantitative Missense Variant Effect Prediction Using Large-Scale Mutagenesis Data. |
| Q38793867 | Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies |
| Q27022790 | Subcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disorders |
| Q38117148 | The Paradox of Akt-mTOR Interactions. |
| Q27852764 | Therapeutic targeting of cancers with loss of PTEN function |
| Q38570349 | Using Genetics to Identify Hereditary Colorectal Polyposis and Cancer Syndromes in Your Patient |
| Q49711122 | Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies |
| Q41932478 | miR-130a deregulates PTEN and stimulates tumor growth |
| Q28389986 | Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pat |
Search more.